Celgene Hands Cancer Drug Back to BeiGene, Plus $150 Million

(Bloomberg) -- Chinese drugmaker BeiGene Ltd. will take back the global rights to its cancer drug tislelizumab from Celgene Corp., following the U.S. company’s blockbuster deal with Bristol-Myers S...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.